Aldeyra Therapeutics (ALDX) Operating Leases (2019 - 2025)
Aldeyra Therapeutics (ALDX) posted Operating Leases of $72536.0 for Q3 2025, down 49.43% on a QoQ basis from $143447.0 in Q2 2025, and up 3.28% year-over-year from $70234.0 in Q3 2024.
Aldeyra Therapeutics (ALDX) Operating Leases (2019 - 2025) Analysis & Trends
Aldeyra Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $72536.0 for Q3 2025.
- Quarterly Operating Leases rose 3.28% year-over-year to $72536.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $72536.0 (up 3.28% YoY) and the FY2023 annual result came in at $271631.0, changed N/A from the prior year.
- Operating Leases was $72536.0 for Q3 2025 at Aldeyra Therapeutics, down from $143447.0 in the prior quarter.
- Across five years, Operating Leases topped out at $271631.0 in Q4 2023 and bottomed at $63325.0 in Q1 2022.
- A 5-year average of $148868.0 and a median of $141170.0 in 2024 frame the typical range for Operating Leases.
- Peak annual rise in Operating Leases reached 3.28% in 2025, while the deepest fall reached 3.28% in 2025.
- Aldeyra Therapeutics' Operating Leases stood at $125232.0 in 2021, then plunged by 49.43% to $63325.0 in 2022, then jumped by 328.95% to $271631.0 in 2023, then sank by 74.14% to $70234.0 in 2024, then grew by 3.28% to $72536.0 in 2025.
- Business Quant data shows ALDX's Operating Leases at $72536.0 in Q3 2025, $143447.0 in Q2 2025, and $212769.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,011.97 Bn | 67,011.68 Bn | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.88 Bn | 467.08 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.20 Bn | 114.96 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.17 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | Aldeyra Therapeutics | 93.80 Mn | 93.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 72,536.00 |
| Jun 30, 2025 | 143,447.00 |
| Mar 31, 2025 | 212,769.00 |
| Sep 30, 2024 | 70,234.00 |
| Jun 30, 2024 | 138,893.00 |
| Mar 31, 2024 | 206,014.00 |
| Dec 31, 2023 | 271,631.00 |
| Mar 31, 2022 | 63,325.00 |
| Dec 31, 2021 | 125,232.00 |
| Sep 30, 2021 | 184,599.00 |
| Sep 30, 2019 | 58,720.00 |
| Jun 30, 2019 | 116,124.00 |
| Mar 31, 2019 | 156,808.00 |